Please login to the form below

Creativity in a complex landscape: a pharma perspective

lue Latitude Health interviewed Mohamed Helal, Marketing Lead for Immunology IBVT at EMEA level for Janssen, to find out his view what an exceptional creative campaign looks like when working at the regional.

"In pharma, there are a lot of rules and regulations that need to be worked within. You always try to be innovative and push the boundaries, but this mindset is difficult in pharma. Even when you think outside the box of traditional marketing, you have to think inside the larger regulatory box"

While all industries face challenges around developing campaigns that are impactful at global, regional, and local levels, pharma has the added challenge of trying to stay innovative and relevant while still remaining within regulatory bounds.

Blue Latitude Health interviewed Mohamed Helal, Marketing Lead for Immunology IBVT at EMEA level for Janssen to understand his point of view on what an exceptional creative campaign when working at the regional level looks like.

Working at the EMEA level, you have to take several different markets’ needs into account when developing campaigns and collateral. In your experience, what are some important factors in making work successful at the regional level?

Mohamed: We have multiple therapy areas in immunology – dermatology, gastroenterology, and rheumatology – and I primarily work with gastroenterology.

Not only are there multiple therapy areas to consider, but also many countries, and anything that is developed at the EMEA level must be relevant to the countries’ needs.
The factors that matter most in making creative work successful are quality, timing, and relevance to the markets.

Deliverables must be straightforward and easy for countries to adapt for their needs, and they must come at the right time. For example, when developing messaging, it’s important to know what restrictions and barriers might come into play for different countries.

Some countries might be allowed to use poster or abstract data in their messaging, while others may only be allowed to use published data.

There might be restrictions in some countries around reimbursement within specific populations, while other countries might be able to develop messaging about the wider population.

Without taking these factors into account, local country uptake of regional work will suffer.

Thinking about how regional work is taken up by individual markets, how does the variance in capabilities at a country level affect the way you approach campaign development? Are there processes or hurdles to take into account?

Because of variation between country level regulations, as well as product lifecycle and brand management, some markets will launch later than others, and this will drive the use of content and materials disseminated to them.

When we develop campaigns at an EMEA level for immunology, we separate our markets into ‘Cocreation’ and ‘Leverage’ markets: 

  •  The Co-creation markets are involved in the process early, helping to guide the development of the campaign, as they will be using regional level materials early on
  •  Leverage markets will receive the regional level tactics and collateral in the rollout phase, as well as best practice and lessons learned by the Co-creation markets from the pilot phase, to guide their own adoption.


Coming back to creative work itself – what makes a piece of creative work stand out to you? What are you looking for in a creative campaign?

Good question! It’s a tough one to answer. In pharma, there are a lot of rules and regulations that need to be worked within. You always try to be innovative and push the boundaries, but this mindset is difficult in pharma.

Even when you think outside the box of traditional marketing, you have to think inside the larger regulatory box.Within broad (and often market-specific) guidance, there are three things that help creative work to stand out as exceptional:

1. It’s representative of the concept behind it – well-developed creative work that is reinforced and underpinned by insight from customers and which brings the concept to life
2. It’s visually engaging and stands out in a sea of competing messages – this is especially important for work that targets HCPs because they receive so many messages on a daily basis
3. The campaign can be easily executed on a practical level – it’s straightforward and simple for country level markets to adapt and roll out. Motivation can be a challenge when asking local markets to adopt regional campaigns, so it’s critical to remove barriers to uptake.

An example of what I would consider an outstanding creative campaign is the ‘Rewrite Their Stories’ campaign for Crohn’s disease, which was shortlisted for a PM Society award earlier this year.

"It got good feedback from physicians who saw it at a congress, who said the campaign was patient-focused, clear, and straightforward.

"The core message spoke to a clear unmet need, and this is something that we find resonates strongly with physicians in immunology."



Download the full article from Blue Latitude Health

21st July 2017

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

What does the future hold for Medical Affairs?
Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
Unpacking rare diseases in the first edition of Delta magazine
Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
Great creative is effective creative. And effective creative is affective creative
Our creative approach at Fishawack Health is Affective Creativity. Creative crafted to make deep, motivating connections with our target audience. We tap into psychology and combine that with creative craft and expertise and to deliver powerful, engaging work on a conscious as well as a subconscious level.
Blue Latitude Health